EP2291553 - SYSTEMS AND METHODS FOR EXPRESSION-BASED DISCRIMINATION OF DISTINCT CLINICAL DISEASE STATES IN PROSTATE CANCER [Right-click to bookmark this link] | Status | The application has been withdrawn Status updated on 04.07.2014 Database last updated on 03.09.2024 | Most recent event Tooltip | 04.07.2014 | Change - divisional application(s) | published on 06.08.2014 [2014/32] | 04.07.2014 | Withdrawal of application | published on 06.08.2014 [2014/32] | Applicant(s) | For all designated states Genomedx Biosciences Inc. 201-1595 3rd Avenue West Vancouver, British Columbia V6J 1J8 / CA | [2011/10] | Inventor(s) | 01 /
DAVICIONI, Elai GenomeDx Biosciences, Inc. 201-1595 W. 3rd Avenue Vancouver British Columbia V6J 1J8 / CA | [2011/10] | Representative(s) | Williams, Richard Andrew Norman, et al HGF Limited 140 London Wall London EC2Y 5DN / GB | [N/P] |
Former [2011/10] | Williams, Richard Andrew Norman, et al Harrison Goddard Foote 40- 43 Chancery Lane London WC2A 1JA / GB | Application number, filing date | 09753364.0 | 28.05.2009 | [2011/10] | WO2009CA00694 | Priority number, date | US20080056827P | 28.05.2008 Original published format: US 56827 P | [2011/10] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2009143603 | Date: | 03.12.2009 | Language: | EN | [2009/49] | Type: | A1 Application with search report | No.: | EP2291553 | Date: | 09.03.2011 | Language: | EN | The application published by WIPO in one of the EPO official languages on 03.12.2009 takes the place of the publication of the European patent application. | [2011/10] | Search report(s) | International search report - published on: | CA | 03.12.2009 | (Supplementary) European search report - dispatched on: | EP | 14.11.2011 | Classification | IPC: | C40B40/06, C12Q1/68, C40B30/04, C07H21/00 | [2011/10] | CPC: |
C12Q1/6886 (EP,US);
C12Q2600/112 (EP,US);
C12Q2600/118 (EP,US);
C12Q2600/158 (EP,US);
Y02A90/10 (EP)
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR [2011/10] | Title | German: | SYSTEME UND VERFAHREN ZUR EXPRESSIONSBASIERTEN UNTERSCHEIDUNG UNTERSCHIEDLICHER KLINISCHER KRANKHEITSSTADIEN BEI PROSTATAKREBS | [2011/10] | English: | SYSTEMS AND METHODS FOR EXPRESSION-BASED DISCRIMINATION OF DISTINCT CLINICAL DISEASE STATES IN PROSTATE CANCER | [2011/10] | French: | SYSTÈMES ET PROCÉDÉS DE DISCRIMINATION BASÉE SUR L EXPRESSION D ÉTATS PATHOLOGIQUES CLINIQUES DISTINCTS DANS LE CANCER DE LA PROSTATE | [2011/10] | Entry into regional phase | 17.12.2010 | National basic fee paid | 17.12.2010 | Search fee paid | 17.12.2010 | Designation fee(s) paid | 17.12.2010 | Examination fee paid | Examination procedure | 17.12.2010 | Examination requested [2011/10] | 11.06.2012 | Amendment by applicant (claims and/or description) | 15.06.2012 | Request for decision received: Application is deemed to be withdrawn | 20.06.2012 | Result of request for decision (Application is deemed to be withdrawn): Request accepted | 10.07.2012 | Despatch of a communication from the examining division (Time limit: M06) | 26.02.2013 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 26.04.2013 | Reply to a communication from the examining division | 01.07.2014 | Application withdrawn by applicant [2014/32] | 16.07.2014 | Date of oral proceedings | Divisional application(s) | EP14175049.7 / EP2806054 | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 10.07.2012 | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 26.04.2013 | Request for further processing filed | 26.04.2013 | Full payment received (date of receipt of payment) Request granted | 10.05.2013 | Decision despatched | Fees paid | Renewal fee | 17.02.2011 | Renewal fee patent year 03 | 28.03.2012 | Renewal fee patent year 04 | 30.05.2013 | Renewal fee patent year 05 | 27.05.2014 | Renewal fee patent year 06 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [I]WO2006110264 (SIDNEY KIMMEL CANCER CT [US], et al) [I] 7-12 * example 2; table 9 *; | [X]US2006046253 (NAKAO YOSHIHIRO [JP], et al) [X] 13 * claims 15, 16; sequence 82625 *; | [I] - BIBIKOVA ET AL, "Expression signatures that correlated with Gleason score and relapse in prostate cancer", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, (20070512), vol. 89, no. 6, doi:10.1016/J.YGENO.2007.02.005, ISSN 0888-7543, pages 666 - 672, XP022077660 [I] 7-12 * figures 3,4; table 1 * DOI: http://dx.doi.org/10.1016/j.ygeno.2007.02.005 | [I] - ANDREW J. STEPHENSON ET AL, "Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy", CANCER, (20050715), vol. 104, no. 2, doi:10.1002/cncr.21157, ISSN 0008-543X, pages 290 - 298, XP055010914 [I] 7-12 * figure 3; tables 2,3 * DOI: http://dx.doi.org/10.1002/cncr.21157 | [I] - GLINSKY G V ET AL, "Gene expression profiling predicts clinical outcome of prostate cancer", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, (20040301), vol. 113, no. 6, doi:10.1172/JCI200420032, ISSN 0021-9738, pages 913 - 923, XP002395330 [I] 7-12 * figures 2-6; tables 1-3 * DOI: http://dx.doi.org/10.1172/JCI200420032 | [XI] - AFFYMETRIX, "GeneChip exon array system for human, mouse, and rat", INTERNET CITATION, (20060101), URL: http://www.affymetrix.com/products/arrays/exon_application.affx, XP002480421 [X] 1-6,13,14 * the whole document * [I] 15 | [A] - RHODES D R ET AL, "Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer", JOURNAL OF THE NATIONAL CANCER INSTITUTE, OXFORD UNIVERSITY PRESS, GB, (20030507), vol. 95, no. 9, ISSN 0027-8874, pages 661 - 668, XP002414584 [A] 7-12 * figures 1,2 * | International search | [X]WO0160860 (MILLENNIUM PREDICTIVE MEDICINE [US]); | [X] - BIBIKOVA, M. ET AL., "Expression signatures that correlated with Gleason score and relapse in prostate cancer.", GENOMICS., (20070424), vol. 89, no. 6, pages 666 - 672, XP022077660 DOI: http://dx.doi.org/10.1016/j.ygeno.2007.02.005 | [A] - COOPER, C. S. ET AL., "Mechanisms of Disease: biomarkers and molecular targets from microarray gene expression studies in prostate cancer.", NAT. CLIN. PRACT. UROL., (200712), vol. 4, no. 12, pages 677 - 687, XP008146613 | [A] - MENDIRATTA, P. ET AL., "Genomic signatures associated with the development, progression, and outcome of prostate cancer.", CANCER., (2007), vol. 11, no. 6, pages 345 - 354, XP008146615 |